Literature DB >> 10841808

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

O Lavergne1, D Demarquay, C Bailly, C Lanco, A Rolland, M Huchet, H Coulomb, N Muller, N Baroggi, J Camara, C Le Breton, E Manginot, J B Cazaux, D C Bigg.   

Abstract

Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone. Combining pronounced inhibitory activity of topoisomerase I (Topo I) with enhanced plasma stability, hCPT constitutes an attractive template for the elaboration of new anticancer agents. Fluorinated hCPT analogues, prepared in enantiomerically pure form, were assayed by their stimulation of Topo I-mediated DNA cleavage. Translation into cytotoxicity against tumor cells was evaluated on HT29 human colon adenocarcinoma and on the multidrug resistant lung and bladder tumor cell lines, A549 and T24r. Good correlation is observed between the ability of the drugs to stimulate Topo I-mediated DNA cleavage and the respective 50% inhibitory concentrations (IC(50) values) of the HT29, A549, and T24r cell growth. Fluorine substitution in the A-ring of hCPT was found to have a pronounced influence on biological activity, providing several compounds which are up to 100-fold more potent than CPT in terms of IC(50). Among these, 10,11-difluoro-hCPT has been selected for further development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841808     DOI: 10.1021/jm000129j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

2.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.